> Press releases 2024

Theranexus joins up with Synerlab to prepare the commercialization of its pediatric formulation in Niemann-Pick type C disease

17/10/2024 18:00
Download PDF File (<1 Mo)

Theranexus announces first half 2024 financial results

26/09/2024 18:00
Download PDF File (<1 Mo)

Semi-annual liquidity contract summary

29/07/2024

Download PDF File (353Ko)

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death

06/06/2024 7:30

Télécharger le PDF (<1Mo)

Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1

11/07/2024 18:30

Télécharger le PDF (<1Mo)

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE “2024 RESEARCH PACT” PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION

03/07/2024 7:30

Télécharger le PDF (<1Mo)

Theranexus, Diverchim and Inserm awarded €4.7 million in funding under the “Innovations in biotherapies and biomanufacturing” call for proposals from France 2030 to develop a novel antisense oligonucleotide

23/04/2024 07h30
Télécharger le PDF (<1Mo)

Theranexus publishes its 2023 full year results and presents its progress report

29/04/2024 18:00

Télécharger le PDF (<1Mo)

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1

18/04/2024 18h00
Télécharger le PDF (<1Mo)

Theranexus announces appointment of Mathieu Charvériat as Board of Directors Chairman 

11/03/2024 8am CET
Download PDF File (<1 Mo)

Theranexus publishes its cash position as of December 31st 2023 and presents an update on its programs 

14/02/2024
Download PDF File (<1 Mo)